A thymosin alpha1 derivative designed for (99m)Tc labelling was made by Fmoc solid-phase synthesis at about 35% overall yield.
In plain wordsIn lab chemistry, a labelable thymosin alpha1 derivative was made with a yield of about 35%.
- Peptide
- Thymosin alpha-1
- Outcome
- Not applicableSynthesis yield of the derivative
- Study
n: not reported in source
solid-phase peptide synthesis of a thymosin alpha1 derivative- Outcome group
- Formulation, delivery and stability · Pharmacology
Measurements
- overall yield
- ≈ 35%
- derivative 1
Source sentences
Synthetic derivative 1 was obtained at high overall yield (approximately 35%)
1 context sentence(design, population, supporting numbers)
A derivative (1) of the immunopotentiating 28-peptide thymosin alpha1 has been especially designed, so that it can be (99m)Tc-radiolabelled, and synthesized following the Fmoc solid-phase peptide synthesis approach.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.